Amarin (AMRN) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amarin (AMRN) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 37.6% versus a loss of 53.4%. Over five years, AMRN leads with a -88.4% price change compared with -93.7% for BCYC. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $253.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | BCYC |
|---|---|---|
| Share price | $11.99 | $3.81 |
| Market cap | $253.26M | $266.67M |
| 1-day change | -0.25% | +2.14% |
| YTD return | -13.90% | -47.32% |
| 1-year return | -37.62% | -53.37% |
| 5-year return | -88.35% | -93.71% |
| Forward P/E | 12.23 | — |
| EPS (TTM) | $-1.20 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $9.16 |
| 52-week low | $11.83 | $3.33 |
| Distance from 52-week high | -42.63% | -58.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +4.25% | +149.34% |
| Average volume | 66.16K | 391.03K |
| Shares outstanding | 21.12M | 50.55M |
| Employees | 80 | 288 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed BCYC by 15.8 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
AMRN vs BCYC FAQ
Which is bigger, Amarin or Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $253.26M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or BCYC?
AMRN returned -37.62% over the past 12 months, compared with -53.37% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.